Alzheimer’s drug slows progression of cognitive decline in clinical trial, drugmakers say

CNN, 7 News WHDH | A monoclonal antibody treatment for Alzheimer’s disease called lecanemab slows the progression of cognitive decline by 27% compared with a placebo, drugmakers Biogen and Eisai said Tuesday. Read more.